Table 1: Comparison of clinical outcome measures pre- and post-infliximab treatment.

Clinical Outcome Pre-Infliximab Treatment Post-Infliximab Treatment
Cutaneous outcome measures:
 mLoSSI (range: 0 – 216) 39 22
 LoSDI (range: 0 – 162) 93 84
Durometer reading (durometer units):
 Upper back- left 24- 35 18- 20
 Upper back- right 25- 38 25- 33
Joint function (all from right side*):
 Upper Extremity
 3rd finger (cm)**
 Extension FTP distance 9.7 10.0
 Flexion FTP distance 2.0 0.7
 Delta Finger-to-palm (FTP) 7.7 9.3
 Elbow 25- 50% limitation 0% limitation
 Lower Extremity
 Hip < 25% limitation 0% limitation
 Knee < 25% limitation 0% limitation
 Ankle 50 – 75% limitation 50 – 75% limitation
 Subtalar 50 – 75% limitation 25 – 50% limitation
Global Assessment of Function:
 Physician
 PGA- Activity 45 0
 PGA- Damage 75 45
 PGA- Severity 80 53
 Patient/Parent
 Patient Global Severity 40 2
 Parent Global Severity Not completed 0
 CDLQI (range 0-30) 9 6

mLoSSI: modified localized scleroderma skin severity index, a composite score to reflect cutaneous disease activity.
LoSDI: localized scleroderma damage index, a composite score to reflect cutaneous disease damage components.
CDLQI: Childhood Dermatology Life Quality Index; higher score indicated higher impact on QOL.
* Both the left and right side affected equally, right represented for simplicity.
** When involvement of all fingers, such as in this patient, the 3rd finger is typically used as the representative finger for finger-to-palm (FTP) measurements, as used in systemic sclerosis.